Table 1 Basic clinical characteristics of the IBD patients and healthy controls
From: Therapeutic potential of the secreted Kazal-type serine protease inhibitor SPINK4 in colitis
N | UC | CD with classical therapy | CD with anti-TNF-α therapy | |
|---|---|---|---|---|
N | 64 | 51 | 43 | 65 |
Male, n (%) | 33 (51.6) | 28 (54.9) | 22 (51.2) | 41 (63.1) |
Median age, yr, (IQR) | 25 (24–28) | 42 (35–56) | 28 (25–36) | 25 (19.75–31.25) |
BMI,kg/m2, (IQR) | - | 19.6 (18.4–23.8) | 18.7 (16.8–20.5) | 19.4 (17.7–21.0) |
Disease phenotype, n (%) | ||||
L1 | - | - | 11 (25.6) | 7 (10.8) |
L2 | - | - | 0 (0) | 3 (4.6) |
L3 | - | - | 30 (69.8) | 55 (84.6) |
L4 | - | - | 2 (4.7) | 0 (0) |
B1 | - | - | 19 (44.2) | 34 (52.3) |
B1p | - | - | 7 (16.3) | 16 (24.6) |
B2 | - | - | 7 (16.3) | 24 (36.9) |
B2p | - | - | 2 (4.7) | 7 (10.8) |
B3 | - | - | 17 (39.5) | 7 (10.8) |
B3p | - | - | 8 (18.6) | 5 (7.7) |
p | - | - | 17 (39.5) | 28 (43.1) |
Disease extent, n (%) | ||||
Proctosigmoiditis | 5 (9.8) | - | - | |
Left‐sided colitis | 14 (27.5) | - | - | |
Pancolitis | 32 (62.7) | - | - | |
